Q&A
After Weight-Loss Collaboration with Novo Nordisk, Omega's New Business Head Seeks More Partners
Omega Therapeutics' new Chief Business Officer, Kaan Certel, said that after completing the weight-loss drug collaboration with Novo Nordisk, the company is actively seeking new partners. Certel emphasized that the interest of large pharmaceutical companies in the platform validates its technological approach, and the reprioritization of pipelines within the industry has created opportunities for small biotech companies.
The Era of Patent Cliffs: New Drug Launches Need to Be Planned Years in Advance
Drug launches are facing multiple challenges, including patent cliffs, regulatory scrutiny, and a tightening investment environment. Eversana CEO Jim Lang states that the industry is entering a recognizable cycle, with large pharmaceutical companies beginning to focus on the CFO and procurement levels throughout the commercialization process. He warns that nearly two-thirds of drug launches fail to meet expectations, and starting preparation two to three years in advance can significantly improve success rates.
The Enhertu Effect: How Daiichi Sankyo Is Building Its Oncology Landscape Around a Core Product
Daiichi Sankyo is experiencing the 'most exciting moment' in its century-long history. With the blockbuster ADC drug Enhertu, developed in partnership with AstraZeneca, the company has established a leading position in the antibody-drug conjugate field and plans to achieve its goal of ranking among the global top-10 oncology companies ahead of schedule through multiple new drug approvals and collaborations.
AstraZeneca Oncology Head: AI Holds Promise to Crack the 'Postcode Lottery' Dilemma in Cancer Care
Amid persistent health inequities, AstraZeneca is leveraging AI collaborations and screening programs to tackle the 'postcode lottery' problem in cancer care. Mohit Manrao, its U.S. oncology head, notes that innovation has outpaced equitable access, and AI could help reveal disparities and improve screening and accessibility through data. However, he also stresses the need to guard against algorithmic bias and ensure AI fairness through diverse biological samples and community partnerships.
How Biotech Executives Can Leverage Big Pharma Experience to Advance tRNA Therapies
Michelle Werner is currently CEO Partner at Flagship Pioneering and CEO of Alltrna, having previously held positions at Bristol-Myers Squibb, AstraZeneca, and Novartis. She is leading Alltrna in advancing tRNA therapies, a platform with the potential to treat thousands of diseases, though it has not yet entered the clinical stage. Werner combines her personal experience with rare diseases and pharmaceutical expertise to drive the company's growth.
Neuroscience Enters a New Era: Industry Calls for 'Moonshot'-Style Breakthroughs
Neuroscience is undergoing a paradigm shift from symptom suppression to fundamental treatment. Dr. Jeremy Levin, CEO of Ovid Therapeutics, points out that technological advances such as small-molecule targeting, AI-assisted drug design, high-resolution MRI, and functional EEG have made 'curing brain diseases' possible. The company's lead candidate, soticlestat, is in Phase III clinical trials and has the potential to become a blockbuster. Levin emphasizes that the industry must learn from failures and focus on the central role of inflammatory mechanisms in various neurological diseases.
AbbVie and Regenxbio bet on one-time gene therapy, aiming at a 'multi-billion dollar opportunity' in the field of vision loss
The gene therapy ABBV-RGX-314, co-developed by Regenxbio and AbbVie, aims to address wet age-related macular degeneration (wet AMD) and diabetic retinopathy through a one-time treatment. Latest data from the Phase 1/2a study show that vision improved or stabilized in most patients after two years. If approved, the therapy could disrupt the existing anti-VEGF drug market, which already generates annual sales exceeding ten billion dollars.
Pharmaceutical M&A Wave Surging, How Does the Technology Sector Address Integration Challenges?
Merger and acquisition activity in the pharmaceutical industry continues to heat up, with technology integration becoming a key element. eClinical Solutions CEO Raj Indupuri points out that data is the most valuable asset in M&A, and industry fragmentation is driving consolidation in the technology sector. This article explores M&A trends, technology challenges, and changes in the regulatory environment.
Verastem CEO prepares for handover as ovarian cancer KRAS combination therapy awaits review
Verastem Oncology plans to submit an accelerated approval application to the FDA for the combination of avutometinib and defactinib in low-grade serous ovarian cancer by the second half of 2025. New CEO Daniel Paterson outlines the company's preparation for the transition from R&D to commercialization, collaborations with Amgen and Mirati, and the broad prospects for RAS pathway therapies.
EMD Serono Executive: Advancing Women in Leadership 'Must Have Clear Goals'
Although the value of women in leadership roles in pharmaceuticals and biotechnology is widely recognized, the gender leadership gap in the industry remains. Lori Lebson, Senior Vice President of Medical Affairs for North America at EMD Serono, emphasizes that diversity does not happen naturally and must have clear goals. She discusses the company's initiatives in women's leadership and points out gaps in the industry regarding funding, mentorship networks, and parenting support.